Recent Pfizer Press Releases

  • 4/26/07 10:48 am EDT
    SOUTH BEND, Ind.--(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We’re operating in an incredibly dynamic industry environment – one that, day in and day out, presents us with a whole range of promising opportunities. To succeed in this environment, we must fundamentally change the way we’ve done business in the past – and eventuallymore...
  • 4/26/07 7:00 am EDT

    Apixaban Currently in Phase III Trials for Prevention of Venous Thromboembolism and Prevention of Stroke Associated with Atrial Fibrillation

    Early-Stage Compounds Being Studied in Treatment of Metabolic Disorders

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) today announced a worldwide collaboration to develop and commercialize apixaban, an anticoagulant discovered by Bristol-Myers Squibb being studied for the prevention and treatment of a broad range of venous and arterial thrombotic conditions. In a separate agreement, the companies will also collaborate on the research, development andmore...
  • 4/24/07 5:43 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0) to recommend the approval of maraviroc, a CCR5 antagonist, for use along with other antiretroviral agents for treatment-experienced patients infected with CCR5-tropic HIV-1. If approved, maraviroc would be the first member of a new class of oral HIV medicines in more than amore...
  • 4/20/07 6:43 am EDT
    • First-Quarter 2007 Revenues Grew 6 Percent to $12.5 Billion, Driven by Growth of New and In-Line Products, Foreign Exchange, and Other Factors
    • First-Quarter 2007 Adjusted Diluted EPS1 Increased 15 Percent to $.68, Reflecting Revenue Growth and Relatively Flat Operating Expenses; First-Quarter 2007 Reported Diluted EPS Decreased 14 Percent to $.48, Primarily Reflecting Restructuring Costs and 2006 One-Time Tax Benefit
    • Pfizer Updates Guidance for Full-Year 2007 Revenues and Full-Year 2007 Reported Diluted EPS and Adjusted Diluted EPS1 in Light of Earlier-than-Anticipated Loss of U.S. Exclusivity for Norvasc
    • Pfizer Provides Updated Guidance Range for Full-Year 2008 Revenues and Reconfirms Guidance for Full-Year 2008 Reported Diluted EPS and Adjusted Diluted EPS1
    • Ten Product Candidates in Cancer Portfolio to be Highlighted at June 2007 ASCO Meeting in 21 Oral Presentations and 49 Abstracts
    • Transformational Efforts Beginning to Show Benefits
    NEW YORK--(BUSINESS WIRE)--Pfizer: ($ billions, except per-share amounts) First Quarter   2007  2006  Revenues $12.474  $11.747  Reported Net Incomemore...
  • 4/19/07 3:41 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 26. To access the Webcast, visit our Website at and click on the “Webcast of the Annual Meeting” link under the “Annual Meeting of Shareholders” section. Pre-registration for the Webcast will be available at that linkmore...
  • 4/9/07 9:58 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2007 Performance Report, to be issued that morning. To listen to the webcast and view the Performance Report, visit our web site homepagemore...
  • 4/2/07 1:38 pm EDT

    Pfizer Discovered and Promptly Reported Subsidiarys Off-Label Marketing of Genotropin to Justice Department, Other Agencies

    NEW YORK--(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges stemming from the off-label marketing of Genotropin — a human growth hormone medicine — and the inappropriate use of a vendor contract to increase the sales of other Pharmacia medicines. Both settlements cover activities that occurred at Pharmacia before thatmore...
  • 3/27/07 1:20 pm EDT

    Patients Who Took Lipitor Had Fewer Cardiovascular Events and Lower Hospitalization Costs Compared with Patients Who Took Simvastatin in the IDEAL Study

    NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by significantly reducing the risk of cardiovascular events in patients with heart disease, according to two separate economic analyses. The data were presented at the annual meeting of the American College of Cardiology. “One of these analyses suggests that even with the availability of lowmore...
  • 3/26/07 4:30 pm EDT

    Lipitor is the Only Statin to Have Been Studied Solely in Patients with Recent Stroke or Mini-stroke

    NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heartmore...
  • 3/26/07 11:27 am EDT

    New Results Build on Previous Data that Lipitor is the Only Statin to Show an Impact in Head-To-Head Imaging Trials

    Separate Analysis Shows Lipitor Cuts the Risk of Coronary Events by Half in Recurrent Stroke Patients

    NEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting ofmore...